Stemline Therap Company Profile
✉ Email this page to a colleague
What is the competitive landscape for STEMLINE THERAP
STEMLINE THERAP has one approved drug.
There are seven US patents protecting STEMLINE THERAP drugs.
There are one hundred and fifty-two patent family members on STEMLINE THERAP drugs in thirty countries and eleven supplementary protection certificates in eleven countries.
Summary for Stemline Therap
| International Patents: | 152 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Stemline Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 10,420,734 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 10,385,008 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 10,745,343 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | 10,745,343 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Stemline Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | 8,399,520 | ⤷ Start Trial |
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | 8,399,520 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Stemline Therap Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102871388 | ⤷ Start Trial |
| San Marino | T202500448 | ⤷ Start Trial |
| China | 117417263 | ⤷ Start Trial |
| Israel | 307981 | ⤷ Start Trial |
| Croatia | P20230365 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Stemline Therap Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3122426 | 2024C/505 | Belgium | ⤷ Start Trial | PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918 |
| 3122426 | 3/2024 | Austria | ⤷ Start Trial | PRODUCT NAME: ELACESTRANT ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1757 (MITTEILUNG) 20230918 |
| 3122426 | LUC00331 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918 |
| 3122426 | C20240005 | Finland | ⤷ Start Trial | |
| 3122426 | 122024000013 | Germany | ⤷ Start Trial | PRODUCT NAME: ELACESTRANT ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1757 20230915 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
